Praxis Precision Medicines, Inc. (PRAX) Balance Sheet

The dramatic asset growth reflects a substantial equity raise, likely in late 2025, which temporarily masks the ongoing operational burn. However, the retained earnings deficit expanded by roughly $300M over the same period, indicating that the cash infusion is being consumed by R&D at an accelerating pace. This suggests the balance sheet is strengthening in nominal terms but weakening in quality, as the company remains dependent on external financing to sustain operations.

The current ratio of 15.73 indicates a strong short-term liquidity position, with cash alone covering nearly ten quarters of operating losses based on the recent burn rate of approximately $80M per quarter. However, this buffer is finite and will erode quickly as late-stage trials escalate costs. Investors should monitor the cash runway closely, as the absence of revenue and reliance on equity financing makes liquidity the primary near-term risk.

The absence of debt simplifies the capital structure and eliminates refinancing risk, but it also means the company has no leverage to cushion equity dilution. With negative retained earnings and no revenue, the balance sheet is entirely equity-funded, making future capital raises the only viable source of liquidity. This structure is typical for clinical-stage biotech but heightens sensitivity to market conditions and investor sentiment.

The equity base has been bolstered by substantial share issuances, as evidenced by the jump in total assets and cash. However, the retained earnings deficit has grown consistently, reflecting that the company is destroying value operationally. The reliance on equity financing means existing shareholders face significant dilution, and the quality of equity is low because it is not generated from profitable operations. This suggests that the balance sheet's apparent strength is a function of financing activity, not business performance.

The asset mix is almost entirely composed of liquid assets, with negligible fixed assets and no intangibles, indicating that the company's value lies in its intellectual property and pipeline, not physical assets. This structure is typical for biotech, but it also means there is little collateral for debt financing and no asset base to cushion against operational setbacks. The minimal PPE suggests reliance on outsourced manufacturing and CROs, which keeps capital intensity low but does not reduce the cash burn.